- Report
- May 2025
- 62 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 166 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 245 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 282 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 382 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 63 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 375 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 360 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 183 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 196 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 181 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 376 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 196 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 194 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 93 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 192 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 89 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 89 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 93 Pages
Global
From €5358EUR$5,850USD£4,561GBP
- Report
- May 2025
- 89 Pages
Global
From €5358EUR$5,850USD£4,561GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more